Social media

The FDA recent draft guidance sets out how Bayesian statistical methods can be applied across drug and biologics development. While Bayesian approaches have been used in medical devices and rare diseases, this is the f...

ICON’s Andrew Garrett and Tim Clark discuss the new FDA Bayesian guidance, which marks a shift toward more efficient clinical trials. https://ow.ly/XeAs50YlTf2

Join ICON at #OCT Southeast on 10–11 March to explore how we support biotech organizations with flexible clinical development solutions, operational expertise and data driven decision making. Visit Booth #37 to meet ou...

Join ICON at #OCT Southeast on 10–11 March to explore how we support biotech organizations with flexible clinical development solutions, operational expertise and data driven decision making. Visit Booth \#37 to meet o...

Latest issue out now. Keep up to date on the most recent regulatory changes in the world of pharma, biotech and medical device clinical trials with ICON’s Regulatory Intelligence Newsletter. Join thousands of subscribe...

Latest issue out now. Keep up to date on the latest changes with ICON’s Regulatory Intelligence Newsletter. Join thousands of subscribers who have discovered the convenience of this free monthly publication by signing ...

Sponsors with multi-indication assets can benefit from taking a precision approach to patient screening that enables stratification by relevant comorbidities and related factors. Learn more trial design considerations ...

At #OCT Southeast on 10–11 March, ICON will showcase the operational, scientific and digital expertise that helps biotechs navigate complexity and deliver studies with greater certainty. Visit Booth \#37 to speak with ...

At #OCT Southeast on 10–11 March, ICON will showcase the operational, scientific and digital expertise that helps biotechs navigate complexity and deliver studies with greater certainty. Visit Booth #37 to speak with o...

Non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinical development. This article in SelectScience® Science explores the evolving NIT landscape, emerging...

Non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinical development. This article in Select Science explores the evolving NIT landscape, emerging regulat...

Join Luke Gregory at #ACDM26 as he explores why artificial intelligence is only one part of a truly effective clinical data science toolkit. Drawing on practical examples, he will show how thoughtful problem assessment, ...